{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:39Z","timestamp":1792831059686,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02304296"],"award-info":[{"award-number":["RS-2025-02304296"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK2631-10"],"award-info":[{"award-number":["KK2631-10"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110615","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:26Z","timestamp":1791389006000},"page":"110615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A natural product-derived degrader (COT-01): cortisone-based CRBN recruitment for cyclin D2 degradation in multiple myeloma"],"prefix":"10.1016","volume":"183","author":[{"given":"Seung Hyeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Dae","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan Jung","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110615_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.89","article-title":"The role of maintenance therapy in multiple myeloma","volume":"6","author":"Lipe","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110615_bb0010","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/CM9.0000000000003655","article-title":"Redefining multiple myeloma treatment: advances, challenges, and future directions in immunotherapy","volume":"138","author":"Fu","year":"2025","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.bioorg.2026.110615_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110615_bb0020","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110615_bb0025","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110615_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0968-0004(00)89005-2","article-title":"D-type cyclins","volume":"20","author":"Sherr","year":"1995","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2026.110615_bb0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110615_bb0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110615_bb0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3324\/haematol.2023.283445","article-title":"Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling","volume":"109","author":"Cardona-Benavides","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110615_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1078-0432.CCR-14-2796","article-title":"Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma","volume":"22","author":"Misiewicz-Krzeminska","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110615_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.44","article-title":"Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations","volume":"2","author":"Glassford","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110615_bb0060","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110615_bb0065","doi-asserted-by":"crossref","first-page":"90501","DOI":"10.18632\/oncotarget.18765","article-title":"The therapeutic potential of cell cycle targeting in multiple myeloma","volume":"8","author":"Maes","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110615_bb0070","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110615_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110615_bb0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110615_bb0085","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110615_bb0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110615_bb0095","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1038\/s41467-024-52871-9","article-title":"Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders","volume":"15","author":"Kroupova","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110615_bb0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110615_bb0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal: An attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110615_bb0110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110615_bb0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110615_bb0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110615_bb0125","doi-asserted-by":"crossref","first-page":"13169","DOI":"10.1021\/acs.jmedchem.5c00783","article-title":"Research progress in targeting GSPT1: molecular glues, bifunctional degraders, and antibody-enabled molecular glues for cancer therapy","volume":"68","author":"Cheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110615_bb0130","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.bioorg.2026.110615_bb0135","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110615_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682601151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682601151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:05:27Z","timestamp":1792829127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682601151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S004520682601151X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110615","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A natural product-derived degrader (COT-01): cortisone-based CRBN recruitment for cyclin D2 degradation in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110615"}}